AIM: To observe and analyze on the incidence rate and causes of complications after anintravitreal injection of bevacizumab.

METHODS: Totally, 207 cases(207 eyes)with wet age-related macular degeneration were selected randomly. All cases were treated with intravitreal injections of bevacizumab(1.5mg/0.06mL)and asked for chief complaints at 1 day, 1 week, 4, 12 weeks after operation, and also examined for routine visual acuity(best corrected visual acuity, BCVA), non-contact tonometer, slit lamp microscope and indirect ophthalmoscope etc.

RESULTS: Among 207 cases(207 eyes), visual acuity improved efficiency was 90.8% 12 weeks after treatment, foreign body sensation was found in 7 cases(3.4%), eyelid skin pruritus in 1 case(0.5%), conjunctival congestion in 6 cases(2.9%), subconjunctival hemorrhage in 1 case(0.5%), post-operative intraocular pressure elevation in 2 cases(1.0%).

CONCLUSION: The intravitreal injection of bevacizumab is effective with fewer complications. We propose to carry out a further randomized multicenter and larger-sample clinical research and further draw up the clinical application criterion of bevacizumab.